Singapore markets closed

WuXi Biologics (Cayman) Inc. (WXIBF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
1.6950-0.1250 (-6.87%)
As of 11:28AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 6.86B
Enterprise value 5.92B
Trailing P/E 15.64
Forward P/E 11.83
PEG ratio (5-yr expected) 0.79
Price/sales (ttm)3.07
Price/book (mrq)1.24
Enterprise value/revenue 2.47
Enterprise value/EBITDA 7.65

Trading information

Stock price history

Beta (5Y monthly) 0.63
52-week change 3-68.90%
S&P500 52-week change 325.26%
52-week high 36.6000
52-week low 31.6300
50-day moving average 31.7971
200-day moving average 33.8471

Share statistics

Avg vol (3-month) 323.13k
Avg vol (10-day) 31.52k
Shares outstanding 54.16B
Implied shares outstanding 64.41B
Float 83.62B
% held by insiders 114.18%
% held by institutions 140.81%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 23:1
Last split date 310 Dec 2020

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 19.96%
Operating margin (ttm)19.09%

Management effectiveness

Return on assets (ttm)4.63%
Return on equity (ttm)8.90%

Income statement

Revenue (ttm)17.03B
Revenue per share (ttm)4.09
Quarterly revenue growth (yoy)6.00%
Gross profit (ttm)N/A
EBITDA 4.93B
Net income avi to common (ttm)3.4B
Diluted EPS (ttm)0.1100
Quarterly earnings growth (yoy)-39.90%

Balance sheet

Total cash (mrq)11.24B
Total cash per share (mrq)2.66
Total debt (mrq)4.56B
Total debt/equity (mrq)10.36%
Current ratio (mrq)2.78
Book value per share (mrq)9.55

Cash flow statement

Operating cash flow (ttm)4.67B
Levered free cash flow (ttm)-320.31M